- Home
- AGEN vs AKA Comparison
AGEN vs AKA Comparison
Compare AGEN & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | AKA |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 116.6M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGEN | AKA |
|---|---|---|
| Price | $3.12 | $10.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.50 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 639.2K | 6.1K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $106,829,000.00 | ★ $595,281,000.00 |
| Revenue This Year | $67.15 | $5.57 |
| Revenue Next Year | N/A | $4.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.44 |
| 52 Week Low | $1.38 | $7.00 |
| 52 Week High | $7.34 | $19.90 |
Technical Indicators
Market Signals| Indicator | AGEN | AKA |
|---|---|---|
| Relative Strength Index (RSI) | 26.40 | 40.44 |
| Support Level | $3.01 | $10.65 |
| Resistance Level | $4.00 | $11.58 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 11.26 | 25.28 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.